CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 136 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,065,000 | +1489.6% | 71,449 | +1073.6% | 0.00% | – |
Q2 2023 | $67,000 | – | 6,088 | +23315.4% | 0.00% | – |
Q1 2023 | $0 | -100.0% | 26 | -99.8% | 0.00% | – |
Q4 2022 | $66,000 | +144.4% | 10,579 | +39.5% | 0.00% | – |
Q3 2022 | $27,000 | +575.0% | 7,581 | +506.5% | 0.00% | – |
Q2 2022 | $4,000 | -75.0% | 1,250 | -76.1% | 0.00% | – |
Q1 2022 | $16,000 | -65.2% | 5,229 | -61.9% | 0.00% | – |
Q4 2021 | $46,000 | +48.4% | 13,711 | +59.3% | 0.00% | – |
Q3 2021 | $31,000 | +14.8% | 8,606 | +39.9% | 0.00% | – |
Q2 2021 | $27,000 | -18.2% | 6,150 | -15.5% | 0.00% | – |
Q1 2021 | $33,000 | +266.7% | 7,278 | +360.6% | 0.00% | – |
Q4 2020 | $9,000 | 0.0% | 1,580 | +24.3% | 0.00% | – |
Q3 2020 | $9,000 | +12.5% | 1,271 | -45.0% | 0.00% | – |
Q2 2020 | $8,000 | -60.0% | 2,313 | -83.4% | 0.00% | – |
Q1 2020 | $20,000 | +1900.0% | 13,972 | +10565.6% | 0.00% | – |
Q3 2019 | $1,000 | 0.0% | 131 | -13.8% | 0.00% | – |
Q2 2019 | $1,000 | -50.0% | 152 | -24.8% | 0.00% | – |
Q1 2019 | $2,000 | +100.0% | 202 | +114.9% | 0.00% | – |
Q4 2018 | $1,000 | -91.7% | 94 | -91.5% | 0.00% | – |
Q3 2018 | $12,000 | -25.0% | 1,107 | -7.8% | 0.00% | – |
Q1 2018 | $16,000 | – | 1,200 | +23900.0% | 0.00% | – |
Q3 2017 | $0 | – | 5 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |